Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Umbrella Protocol for Phase I/IIa Trials of Molecularly Matched Targeted Therapies Plus Radiotherapy in Patients With Newly Diagnosed Glioblastoma Without MGMT Promoter Methylation: NCT Neuro Master Match - N²M² (NOA-20)

NCT03158389 is registered in ClinicalTrials.gov with University Hospital Heidelberg as lead sponsor.

NCT NCT03158389
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03158389 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Umbrella Protocol for Phase I/IIa Trials of Molecularly Matched Targeted Therapies Plus Radiotherapy in Patients With Newly Diagnosed Glioblastoma Without MGMT Promoter Methylation: NCT Neuro Master Match - N²M² (NOA-20)
Lead sponsor
University Hospital Heidelberg
Phase
Phase 1/2
Overall status
Completed
Start date
May 7, 2018
Completion date
February 22, 2023
Enrollment
228 (actual)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

glioblastoma, adult